SlideShare a Scribd company logo
1 of 25
MYTH BUSTERS- Linagliptin in renal perspective
DR LALIT KUMAR AGARWAL NEPHROLOGIST
• Diabetes is the most common reason
for progression to ESRD in many
parts of the world1−3
• CKD is the one of the strongest
predictor of mortality in patients
with diabetes4−6
• CKD occurs as a consequence of
multiple pathogenic pathways in the
diabetic kidney1
– Hyperglycaemia(glucotoxicity) plays a
major, but not exclusive role
CKD, chronic kidney disease; ESRD, end-stage renal disease; T2D, type 2 diabetes
1. Toth-Manikowski S & Atta MG. J Diabetes Res 2015;2015:697010;2. Stewart JH et al. Nephrology 2007;12:520; 3. Thomas MC et al. Nat Rev Nephrol 2016;12:73;
4. Reidy K et al. J Clin Invest 2014;124:2333; 5. United States Renal Data System. Am J Kidney Dis 2003;42:1; 6. Afkarian M et al. J Am Soc Nephrol 2013;24:302;
7. National Kidney Foundation. Diabetes. 2015. www.kidney.org/atoz/content/diabetes (Accessed Sep 2017)
Diabetes leads to micro and macrovascular complications
Approximately 50% of
those with T2D will
eventually suffer from
CKD3,7
~50%
0
15
30
45
60
75
N=6,034 N=11,253 N=4,685 N=2,437
All-cause
mortality
rate
(per
1000
person-years)
3
Kidney disease is a stronger risk factor for mortality than a prior
CV event
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction
Tonelli M et al. Lancet 2012;380:807-814
Previous MI
Diabetes + CKD
CKD
(eGFR <60)
Diabetes
2x
T2D, type 2 diabetes; GFR, glomerular filtration rate
Percentages indicate excess mortality above the reference group (individuals with no diabetes or kidney disease) Afkarian M et al. J Am Soc Nephrol 2013;24:302
Patients with T2D and kidney disease have higher mortality
rates than those without kidney disease
10
0
20
30
40
60
50
70
No kidney disease Albuminuria Impaired GFR Albuminuria &
impaired GFR
Reference group
Standardised
10-year
cumulative
incidence
of
mortality
(%)
4.1
17.8
23.9
47.0
Excess
mortality
Increased
mortality
T2D –CKD-CVD : The connecting link
5
CKD, chronic kidney disease
Moen MF et al. Clin J Am Soc Nephrol 2009;4:1121
Risk of hypoglycaemia is increased in CKD
8.4
4.1
1.6
1.0
1
0
2
4
3
5
8
7
6
9
+CKD/
+diabetes
–CKD/
+diabetes
+CKD/
–diabetes
–CKD/
–diabetes
Risk
of
severe
hypoglycaemia
(incidence
rate
ratio)
With declining renal
function, there is decreased
clearanceof insulin.
Challenges in optimising glycaemic control in CKD
The management of glucose levels is particularly challenging in these patients, with the
concomitant need to avoid hypoglycaemic events while managing renal comorbidities, often
accompanied by CVD and/or other significant comorbidities2
Dose adjustment or
cessation may be required
for oral antidiabetic agents
excreted by the kidney1
With declining renal
function, there is
decreased clearance of
insulin1
Need to avoid
hypoglycemia
Reduced renal gluconeogenesis
with declining renal mass1
CKD, chronic kidney disease; CVD cardiovascular disease.
1. KDOQI. Am J Kidney Dis 2012;60: 850–86. 2. Sherwin et al. J Clin Invest 1976;57: 722–31. 3. Defronzo et al. J Clin Invest 1978;62: 425–35.
 Concern regarding the long term CV and renal safety of anti-hyperglcemic
agents have been raised in several studies following publication of meta-
analysis in 2007 that ROSIGLITAZONE increased the risk of MI and in 2009,
RECORD trial showed that adding ROSIGLITAZONE increased the risk of heart
failure
 DDP4 Inhibitor – the net effect is a reduction in glucagon level and increased
INSULIN secretion.
 Most of the DPP4 inhibitors have neutral effects on CV events(proved by
many CVOT trials).
 LINAGLIPTIN is safe for CV and RENAL side effects.(CARMELINA TRIAL in
subjects with high cardio-renal risks)
ANTI HYPERGLYCEMIC AGENTS CHOICE: Concern on long term CV and renal safety -
8
9
CARMELINA® was specifically designed and statistically powered
to evaluate both CV and Kidney Outcomes
CARMELINA: Pre-specified adjudicated composite renal endpoints
 Sustained ESRD
 Sustained reduction in eGFR >40%
 Renal Death
1. Scirica BM et al. N Engl J Med 2013;369:1317; 2. White WB et al. N Engl J Med 2013;369:1327; 3. Green JB et al. N Engl J Med 2015;373:232; 4. Rosenstock J et al. Cardiovasc Diabetol 2018;17:39
Renal safety and potential benefits of Linagliptin has been proven with
CARMELINA.
Perception : All DPP-4i are kidney safe, it is not exclusive to Linagliptin
What could be the clinical impact of a prespecified renal
endpoint safety evidence as recorded from the CARMELINA
trial?
EXPERT OPINION
Linagliptin has proven Safety and Effectiveness
Across the Spectrum of Chronic Kidney Disease
Mild RI1
Moderate RI1
Severe RI2
ESRD and
Hemodialysis3
New - Onset Diabetes
After Transplant4
-0.7%
-0.7%
-0.7%
-1%
-0.6%
1. Cooper M, et al. ADA 2011, Poster 1068-P. 2. McGill JB, et al. Diabetes Care. 2013;36:237–244. 3. Kono T et al. 58th Ann Mtg of the Japanese Society for Dialysis Therapy (JSDT),
Fukuoka, J Jpn Soc Dial Ther 2013. 46 (Suppl 1):670. 4. Sanyal, et al Indian J Endocr Metab 2013;17:S203-5. 5. Bae J et al. Endocrinol Metab (Seoul). 2016 Jan 6. PMID: 26754588
HbA1c Reductions
with Linagliptin
Across CKD Spectrum
-1.4%
Diabetes in Renal
Transplant5
Preserved eGFR
over 1-year2
CV safety of DPP-4i in patients with kidney disease has been
appropriately studied in CARMELINA
11
Schernthaner, Guntram et al.Diabetes Research and Clinical Practice, Volume 153, 30 - 4
The safety of
linagliptin in
patients with kidney
disease, has been
appropriately
studied only in
CARMELINA: 74% of
trial population
were having
‘prevalent kidney
disease‘*
*Defined as eGFR <60 ml/min/1.73 m2 or macroalbuminuria (UACR ≥300 mg/g
CARMELINA demonstrated long-term kidney safety with
Linagliptin
CV, cardiovascular; CVOT, cardiovascular outcomes trial; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease;
VEGF, vascular endothelial growth factor
†ESKD, renal death, ≥50% decrease in eGFR, albuminuria progression, use of retinal photocoagulation or intravitreal injections of an anti-VEGF therapy for diabetic retinopathy, or vitreous haemorrhage or
diabetes-related-blindness
1. Scirica BM et al. N Engl J Med 2013;369:1317; 2. White WB et al. N Engl J Med 2013;369:1327; 3. Green JB et al. N Engl J Med 2015;373:232; 4. Boehringer Ingelheim. Data on file. 2018 12
HR (95% CI) HR (95% CI) p-value
Prespecified adjudicated kidney composite
outcome
Other DPP-4i CVOTs
1-3
Not studied
ESKD, renal death or ≥40% eGFR decrease
4
1.04 (0.89, 1.22) 0.6164
ESKD or renal death 0.87 (0.69, 1.10) 0.2371
Prespecified microvascular composite outcome
†
0.86 (0.78, 0.95) 0.0032
Albuminuria progression 0.86 (0.78, 0.95) 0.0034
0.5 1.0 2.0
Favours linagliptin Favours placebo
?
13
UACR reduction ≥50%
14% Lower Risk of
Progression of Albuminuria
14%
RRR
15% Greater Likelihood of
Significant Regression in UACR
15%
Learnings from CARMELINA Trial:
Risk Reduction for Albuminuria with Linagliptin
Julio Rosenstock, Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High
Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial, JAMA, nov 2018
Participants: Type 2 DM Plus CVD or Renal disease
Interventions: 5mg Linagliptin vs Placebo
Outcomes: 3P-MACE, Kidney outcome
Conclusion: Individuals with T2D and NRP having a high disease burden, Linagliptin reduces
their albuminuria burden and HbA1c, without affecting CV or kidney risk.
14
Reno-protective effects of linagliptin
1,2
 Inhibition of podocyte injury and apoptosis
 Inhibition of myofibroblast transformation
 Increased GLP-1 receptor expression
1. Mima A et al. Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes. Sci Rep. 2020; 10: 5775.79-7
2. Sharkovska Y. J Hypertens. 2014 Nov;32(11):2211-23
Possible Mechanisms for Kidney Protection in Pre-clinical
Studies
• Linagliptin can inhibit endothelial to
mesenchymal transition (EndMT), thus
ameliorates diabetic kidney fibrosis and
progressive CKD
• Such effects of Linagliptin were drug-
specific, but not class effects
 Linagliptin did not affect glomerular filtration rate (GFR), effective renal plasma flow
(ERPF) or any intrarenal hemodynamic functions, compared to Glimepiride
 Linagliptin was associated with modest natriuresis, possibly mediated by SDF-1α, with
increase in fractional excretion of sodium (FENa) and potassium (FEK)
The RENALIS Study:
Effect of Linagliptin on Fasting Renal Hemodynamics
16
After 8 weeks of treatment in overweight T2D patients without renal impairment:
Muskiet MHA, et al. Diabetes Care 2020;dc200902 [DOI: 10.2337/dc20-0902]
With its unique mode of elimination, Linagliptin is the only available DPP-4 inhibitor
that does not require dose adjustment for any stage of renal impairment
Perception : Linagliptin is useful only in T2D with CKD Patients
Any opinion regarding the same?
Baseline Characteristics of DPP-4i CVOTs
18
Renal Risk
Cardiovascular
Risk
Low CV & Kidney Risk
High CV Risk High CV & Kidney Risk
With CARMELINA & CAROLINA,
linagliptin has been studied in
Patients across
Cardio-Renal Risk Continuum
Median T2D duration
6.3 years
Median T2D duration
14.75 years
Jennifer B. Green, Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes, n engl j med 373;3 nejm.org july 16, 2015. Benjamin M. Scirica,, Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, n engl j med 369;14 nejm.org october 3,
2013. William B. White, Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes, n engl j med 369;14 nejm.org october 3, 2013. Julio Rosenstock, Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High
Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial, JAMA. doi:10.1001/jama.2018.18269 Published online November 9, 2018. Julio Rosenstock, Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
The CAROLINA Randomized Clinical Trial, JAMA. 2019;322(12):1155-1166. doi:10.1001/jama.2019.13772 Published online September 19, 2019.
CAROLINA® and CARMELINA® provide evidence across a
broad spectrum of T2D disease duration, CV and kidney risk
CV, cardiovascular; T2D, type 2 diabetes
1. Rosenstock J et al. ADA 2019; 2. Rosenstock J et al. JAMA 2019;321:69
19
Atherosclerosis
Chronic kidney disease
Target-organ damage
Risk
42%
Median T2D
duration
6.3 years
Had established
CV disease
Displayed ≥2
defined CV risk
factors
Had T2D for
≤5 years
Active-
comparator
Treatment
naïve
On insulin
On metformin
37%
40%
9%
0%
83% 74%
Mean T2D
duration
14.75 years
Prevalent kidney
disease
Had established
CV disease
Had established
CV disease and
prevalent kidney
disease
Placebo-
controlled
Treatment naïve
On metformin
On insulin
57%
33%
<3%
55%
58%
Early
disease
Advanced
disease
CAROLINA®1 CARMELINA®2
Asymptomatic Symptomatic
CAROLINA® Linagliptin, n/N (%) Glimepiride, n/N (%) HR (95% CI) p-value
3P-MACE 356/3023 (11.8) 362/3010 (12.0) 0.98 (0.84, 1.14)* 0.7625
HHF or CV death 236/3023 (7.8) 234/3010 (7.8) 1.00 (0.84, 1.20) 0.9671
All-cause mortality 308/3023 (10.2) 336/3010 (11.2) 0.91 (0.78, 1.06) 0.2263
Together CARMELINA and CAROLINA Demonstrate Long-term
Safety of Linagliptin in Patients Across Cardio-renal Risk Continuum
CARMELINA® Linagliptin, n/N (%) Placebo, n/N (%) HR (95% CI) p-value
3P-MACE 434/3494 (12.4) 420/3485 (12.1) 1.02 (0.89, 1.17) 0.7398
HHF or CV death 406/3494 (11.6) 422/3485 (12.1) 0.94 (0.82, 1.08) 0.3881
All-cause mortality 367/3494 (10.5) 373/3485 (10.7) 0.98 (0.84, 1.13) 0.7402
*95.47 CI. 3P-MACE, 3-point MACE; 4P-MACE, 4-point MACE; CV, cardiovascular; HF, heart failure;
HHF, hospitalisation for HF; MACE, major adverse CV events; MI, myocardial infarction
Rosenstock J et al. JAMA 2019;321:69; Rosenstock J et al. ADA 2019
Linagliptin has Proven CV and Renal Safety
Across the Spectrum of CKD in T2DM
*P value of subgroup-by-treatment interaction test.
Adapted: Perkovic V et al. Diabetes Care. 2020 May 22;dc200279
CARMELINA Study: Patients of T2DM with CVD and/or CKD
Linagliptin Placebo
HR (95% CI) HR (95% CI)
p-value for
treatment by age
interaction
n with event / N analysed (%)
3P-MACE 434/3494 (12.4) 420/3485 (12.1) 1.02 (0.89, 1.17) 0.0937
<65 years 154/1467 (10.5) 140/1501 (9.3) 1.11 (0.89, 1.40)
65 to <75 years 197/1405 (14.0) 182/1395 (13.0) 1.09 (0.89, 1.33)
≥75 years 83/622 (13.3) 98/589 (16.6) 0.76 (0.57, 1.02)
HHF 209/3494 (6.0) 226/3485 (6.5) 0.90 (0.74, 1.08) 0.9788
<65 years 67/1467 (4.6) 77/1501 (5.1) 0.87 (0.63, 1.21)
65 to <75 years 89/1405 (6.3) 99/1395 (7.1) 0.89 (0.67, 1.18)
≥75 years 53/622 (8.5) 50/589 (8.5) 0.92 (0.63, 1.35)
Kidney outcome* 327/3494 (9.4) 306/3485 (8.8) 1.04 (0.89, 1.22) 0.9968
<65 years 180/1467 (12.3) 173/1501 (11.5) 1.05 (0.85, 1.29)
65 to <75 years 113/1405 (8.0) 105/1395 (7.5) 1.06 (0.81, 1.38)
≥75 years 34/622 (5.5) 28/589 (4.8) 1.06 (0.64, 1.75)
Albuminuria progression 763/2162 (35.3) 819/2129 (38.5) 0.86 (0.78, 0.95) 0.4318
<65 years 289/816 (35.4) 308/829 (37.2) 0.93 (0.79, 1.09)
65 to <75 years 320/903 (35.4) 339/877 (38.7) 0.84 (0.72, 0.98)
≥75 years 154/443 (34.8) 172/423 (40.7) 0.78 (0.63, 0.97)
CARMELINA: No increased risk of cardio-renal events in older
patients
0.25 0.5 1 2 4
Favours linagliptin Favours placebo
*Death due to kidney disease, progression to end-stage kidney disease, or sustained decrease in estimated glomerular filtration rate from baseline of ≥40%
Cooper M et al. Diabetes Obes Metab 2020; Feb 9. doi: 10.1111/dom.13995 [Epub ahead of print]
Summary: Linagliptin has Broadest Clinical Evidence in DPP-4i
class
23
Uncertain
Proven safety
High CV risk Heart failure High kidney risk
Proven safety Proven safety
Safety Signal
Proven safety
Proven safety Uncertain
Proven safety
Uncertain
Uncertain
Safety signal
Uncertain‡ Uncertain Uncertain
Sitagliptin4, 5, 6
Teneligliptin3, 8
Linagliptin7
Saxagliptin2
Vildagliptin1
1. Novartis Europharm Ltd. Galvus® (vildagliptin) summary of product characteristics; 2. Scirica B et al. N Engl J Med 2013;369:1317; 3. Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):11-17; 4. Green J et al. N Engl J Med
2015;373:232; 5. Engel SE et al. Diabetes Obes Metab 2017;19:1587; 6. Merck Sharp & Dohme Ltd. Januvia® (sitagliptin) summary of product characteristics; 7. Trajenta PI 9 April 2020. Boehringer Ingelheim. 8. Singh AK.
Efficacy and safety of teneligliptin. Indian J Endocr Metab 2017;21:11-7.
+ convenience of OD dosing without the need of dose adjustment
Summary : Simplifying T2DM Care with Linagliptin
24
Proven Effectiveness and Safety
Across Broad Range of Patients
No need for dose-adjustment, in
any stage of CKD
Long Half-life (>100 hours), Ensuring
Effective 24-hour Glycaemia Control
5mg one dose, once daily
independent of:
CV Risk
Trajenta PI Boehringer Ingelheim Pvt. Ltd. 09 Apr 2020
Thank You !

More Related Content

What's hot

SGLT2 inhibitors in Diabetic Kidney Disease
SGLT2 inhibitors in Diabetic Kidney DiseaseSGLT2 inhibitors in Diabetic Kidney Disease
SGLT2 inhibitors in Diabetic Kidney DiseaseChristos Argyropoulos
 
SGLT2 inhibitor -A boon in uncontrolled dm
SGLT2 inhibitor -A boon in uncontrolled dmSGLT2 inhibitor -A boon in uncontrolled dm
SGLT2 inhibitor -A boon in uncontrolled dmdr nirmal jaiswal
 
sitagliptin for diabetics
sitagliptin for diabeticssitagliptin for diabetics
sitagliptin for diabeticsMahmoud Yossof
 
Dpp4i earlier the better ! (1)
Dpp4i  earlier the better ! (1)Dpp4i  earlier the better ! (1)
Dpp4i earlier the better ! (1)Faraz Farishta
 
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...magdy elmasry
 
Sodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitorsSodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitorsMoh'd sharshir
 
Are all DPP4 inhibitors the same.pptx
Are all DPP4 inhibitors the same.pptxAre all DPP4 inhibitors the same.pptx
Are all DPP4 inhibitors the same.pptxShreeBajrangdasbapaA
 
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...SYEDRAZA56411
 

What's hot (20)

SGLT2 inhibitors in Diabetic Kidney Disease
SGLT2 inhibitors in Diabetic Kidney DiseaseSGLT2 inhibitors in Diabetic Kidney Disease
SGLT2 inhibitors in Diabetic Kidney Disease
 
SGLT2i
SGLT2iSGLT2i
SGLT2i
 
Dapagliflozin
DapagliflozinDapagliflozin
Dapagliflozin
 
SGLT-2
SGLT-2 SGLT-2
SGLT-2
 
SGLT2 inhibitor -A boon in uncontrolled dm
SGLT2 inhibitor -A boon in uncontrolled dmSGLT2 inhibitor -A boon in uncontrolled dm
SGLT2 inhibitor -A boon in uncontrolled dm
 
sitagliptin for diabetics
sitagliptin for diabeticssitagliptin for diabetics
sitagliptin for diabetics
 
Dpp4i earlier the better ! (1)
Dpp4i  earlier the better ! (1)Dpp4i  earlier the better ! (1)
Dpp4i earlier the better ! (1)
 
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials  ...
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...
 
glyxambi
glyxambiglyxambi
glyxambi
 
SGLT2 inhibitor trials
SGLT2 inhibitor trialsSGLT2 inhibitor trials
SGLT2 inhibitor trials
 
Sodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitorsSodium glucose cotransporter 2 (sglt2) inhibitors
Sodium glucose cotransporter 2 (sglt2) inhibitors
 
Diabetic Kidney Disease 2022 Update
Diabetic Kidney Disease 2022 UpdateDiabetic Kidney Disease 2022 Update
Diabetic Kidney Disease 2022 Update
 
Presentation sitagliptin
Presentation sitagliptinPresentation sitagliptin
Presentation sitagliptin
 
Are all DPP4 inhibitors the same.pptx
Are all DPP4 inhibitors the same.pptxAre all DPP4 inhibitors the same.pptx
Are all DPP4 inhibitors the same.pptx
 
Role of SGLT2i in cardio-renal protection
Role of SGLT2i in cardio-renal protectionRole of SGLT2i in cardio-renal protection
Role of SGLT2i in cardio-renal protection
 
GLP-1 and Diabetes Mellitus
GLP-1 and Diabetes MellitusGLP-1 and Diabetes Mellitus
GLP-1 and Diabetes Mellitus
 
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada SelimEmpagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
 
Vildagliptin
Vildagliptin Vildagliptin
Vildagliptin
 
Sitagliptin
SitagliptinSitagliptin
Sitagliptin
 
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
Role of Dapagliflozin in the management of Diabetes and prevention of cardiac...
 

Similar to Carmelina

Dm and kidney August 23 2019
Dm and kidney August 23 2019Dm and kidney August 23 2019
Dm and kidney August 23 2019Ala Ali
 
Care of patients with diabetic kidney disease
Care of patients with diabetic kidney diseaseCare of patients with diabetic kidney disease
Care of patients with diabetic kidney diseaseJimRitchie14
 
Ueda2015 unmet medical needs in dm dr.lobna el-toony
Ueda2015 unmet medical needs in dm dr.lobna el-toonyUeda2015 unmet medical needs in dm dr.lobna el-toony
Ueda2015 unmet medical needs in dm dr.lobna el-toonyueda2015
 
Diabetes management in hemodialysis by prof alaa wafa
Diabetes management in hemodialysis by prof alaa wafaDiabetes management in hemodialysis by prof alaa wafa
Diabetes management in hemodialysis by prof alaa wafaalaa wafa
 
Diabetes,dysglycemia; and chronic kidney disease by prof alaa wafa
Diabetes,dysglycemia; and chronic kidney disease by prof alaa wafaDiabetes,dysglycemia; and chronic kidney disease by prof alaa wafa
Diabetes,dysglycemia; and chronic kidney disease by prof alaa wafaalaa wafa
 
Ueda2016 symposium - managing special population in diabetic patient,vildagli...
Ueda2016 symposium - managing special population in diabetic patient,vildagli...Ueda2016 symposium - managing special population in diabetic patient,vildagli...
Ueda2016 symposium - managing special population in diabetic patient,vildagli...ueda2015
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsPHAM HUU THAI
 
Pores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapyPores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapyOsama Almaraghi
 
MCDP_Renal.pdf
MCDP_Renal.pdfMCDP_Renal.pdf
MCDP_Renal.pdfHanaDalila
 
Diabetic Kidney Disease
Diabetic Kidney DiseaseDiabetic Kidney Disease
Diabetic Kidney Diseasedrsanjaymaitra
 
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...cacao83
 
Management of Diabetes in Dialysis Patients
Management of Diabetes in Dialysis PatientsManagement of Diabetes in Dialysis Patients
Management of Diabetes in Dialysis PatientsChristos Argyropoulos
 

Similar to Carmelina (20)

Dm and kidney August 23 2019
Dm and kidney August 23 2019Dm and kidney August 23 2019
Dm and kidney August 23 2019
 
Care of patients with diabetic kidney disease
Care of patients with diabetic kidney diseaseCare of patients with diabetic kidney disease
Care of patients with diabetic kidney disease
 
Ueda2015 unmet medical needs in dm dr.lobna el-toony
Ueda2015 unmet medical needs in dm dr.lobna el-toonyUeda2015 unmet medical needs in dm dr.lobna el-toony
Ueda2015 unmet medical needs in dm dr.lobna el-toony
 
Diabetes management in hemodialysis by prof alaa wafa
Diabetes management in hemodialysis by prof alaa wafaDiabetes management in hemodialysis by prof alaa wafa
Diabetes management in hemodialysis by prof alaa wafa
 
Diabetes,dysglycemia; and chronic kidney disease by prof alaa wafa
Diabetes,dysglycemia; and chronic kidney disease by prof alaa wafaDiabetes,dysglycemia; and chronic kidney disease by prof alaa wafa
Diabetes,dysglycemia; and chronic kidney disease by prof alaa wafa
 
Ueda2016 symposium - managing special population in diabetic patient,vildagli...
Ueda2016 symposium - managing special population in diabetic patient,vildagli...Ueda2016 symposium - managing special population in diabetic patient,vildagli...
Ueda2016 symposium - managing special population in diabetic patient,vildagli...
 
CARDIO_Duo
CARDIO_Duo CARDIO_Duo
CARDIO_Duo
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
 
Pores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapyPores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapy
 
Bydureon
BydureonBydureon
Bydureon
 
MCDP_Renal.pdf
MCDP_Renal.pdfMCDP_Renal.pdf
MCDP_Renal.pdf
 
Actos
ActosActos
Actos
 
Diabetic Kidney Disease
Diabetic Kidney DiseaseDiabetic Kidney Disease
Diabetic Kidney Disease
 
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
Thuốc điều trị tăng huyết áp trên bệnh thận đái tháo đường - BS Phạm Văn Bù...
 
Management of Diabetes in Dialysis Patients
Management of Diabetes in Dialysis PatientsManagement of Diabetes in Dialysis Patients
Management of Diabetes in Dialysis Patients
 
Type 2 DM and CKD
Type 2 DM and CKDType 2 DM and CKD
Type 2 DM and CKD
 
Diabetic kidney disease 2021
Diabetic kidney disease 2021 Diabetic kidney disease 2021
Diabetic kidney disease 2021
 
Diabetic nephropathy, patho physiology update
Diabetic nephropathy, patho physiology updateDiabetic nephropathy, patho physiology update
Diabetic nephropathy, patho physiology update
 
DM Pathogenesis.pdf
DM Pathogenesis.pdfDM Pathogenesis.pdf
DM Pathogenesis.pdf
 
KDIGO CKD 2012
KDIGO CKD 2012KDIGO CKD 2012
KDIGO CKD 2012
 

More from Dr. Lalit Agarwal

Woodlands.world kidney day 2020
Woodlands.world kidney day 2020Woodlands.world kidney day 2020
Woodlands.world kidney day 2020Dr. Lalit Agarwal
 
Management of poisoning by extracorporeal treatments
Management of poisoning by extracorporeal treatmentsManagement of poisoning by extracorporeal treatments
Management of poisoning by extracorporeal treatmentsDr. Lalit Agarwal
 
Overview of kidney transplant
Overview of kidney transplantOverview of kidney transplant
Overview of kidney transplantDr. Lalit Agarwal
 
Timing for initiation of dialysis.
Timing for initiation of dialysis.Timing for initiation of dialysis.
Timing for initiation of dialysis.Dr. Lalit Agarwal
 

More from Dr. Lalit Agarwal (9)

Albumin and Nephrology.pptx
Albumin and Nephrology.pptxAlbumin and Nephrology.pptx
Albumin and Nephrology.pptx
 
invasive candidisis.pptx
invasive candidisis.pptxinvasive candidisis.pptx
invasive candidisis.pptx
 
Woodlands.world kidney day 2020
Woodlands.world kidney day 2020Woodlands.world kidney day 2020
Woodlands.world kidney day 2020
 
New uric acid disorder
New uric acid disorderNew uric acid disorder
New uric acid disorder
 
Management of poisoning by extracorporeal treatments
Management of poisoning by extracorporeal treatmentsManagement of poisoning by extracorporeal treatments
Management of poisoning by extracorporeal treatments
 
Overview of kidney transplant
Overview of kidney transplantOverview of kidney transplant
Overview of kidney transplant
 
Uric acid disorders
Uric acid disordersUric acid disorders
Uric acid disorders
 
Timing for initiation of dialysis.
Timing for initiation of dialysis.Timing for initiation of dialysis.
Timing for initiation of dialysis.
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
 

Recently uploaded

(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...parulsinha
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...chandars293
 
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...GENUINE ESCORT AGENCY
 
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service AvailableCall Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service AvailableDipal Arora
 
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In AhmedabadGENUINE ESCORT AGENCY
 
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service AvailableTrichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service AvailableGENUINE ESCORT AGENCY
 
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...khalifaescort01
 
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Tirupati Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service AvailableDipal Arora
 
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...Arohi Goyal
 
Most Beautiful Call Girl in Bangalore Contact on Whatsapp
Most Beautiful Call Girl in Bangalore Contact on WhatsappMost Beautiful Call Girl in Bangalore Contact on Whatsapp
Most Beautiful Call Girl in Bangalore Contact on WhatsappInaaya Sharma
 
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...chetankumar9855
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...hotbabesbook
 
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...vidya singh
 
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...parulsinha
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...aartirawatdelhi
 
Call Girls Visakhapatnam Just Call 8250077686 Top Class Call Girl Service Ava...
Call Girls Visakhapatnam Just Call 8250077686 Top Class Call Girl Service Ava...Call Girls Visakhapatnam Just Call 8250077686 Top Class Call Girl Service Ava...
Call Girls Visakhapatnam Just Call 8250077686 Top Class Call Girl Service Ava...Dipal Arora
 
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...Sheetaleventcompany
 
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋TANUJA PANDEY
 
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...Ishani Gupta
 

Recently uploaded (20)

(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
(Low Rate RASHMI ) Rate Of Call Girls Jaipur ❣ 8445551418 ❣ Elite Models & Ce...
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
 
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
Pondicherry Call Girls Book Now 9630942363 Top Class Pondicherry Escort Servi...
 
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service AvailableCall Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
 
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
 
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service AvailableTrichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
 
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
💕SONAM KUMAR💕Premium Call Girls Jaipur ↘️9257276172 ↙️One Night Stand With Lo...
 
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Tirupati Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Tirupati Just Call 8250077686 Top Class Call Girl Service Available
 
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
 
Most Beautiful Call Girl in Bangalore Contact on Whatsapp
Most Beautiful Call Girl in Bangalore Contact on WhatsappMost Beautiful Call Girl in Bangalore Contact on Whatsapp
Most Beautiful Call Girl in Bangalore Contact on Whatsapp
 
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
 
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
 
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
 
Call Girls Visakhapatnam Just Call 8250077686 Top Class Call Girl Service Ava...
Call Girls Visakhapatnam Just Call 8250077686 Top Class Call Girl Service Ava...Call Girls Visakhapatnam Just Call 8250077686 Top Class Call Girl Service Ava...
Call Girls Visakhapatnam Just Call 8250077686 Top Class Call Girl Service Ava...
 
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
Call Girls Service Jaipur {9521753030} ❤️VVIP RIDDHI Call Girl in Jaipur Raja...
 
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
 
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋
 
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
 

Carmelina

  • 1. MYTH BUSTERS- Linagliptin in renal perspective DR LALIT KUMAR AGARWAL NEPHROLOGIST
  • 2. • Diabetes is the most common reason for progression to ESRD in many parts of the world1−3 • CKD is the one of the strongest predictor of mortality in patients with diabetes4−6 • CKD occurs as a consequence of multiple pathogenic pathways in the diabetic kidney1 – Hyperglycaemia(glucotoxicity) plays a major, but not exclusive role CKD, chronic kidney disease; ESRD, end-stage renal disease; T2D, type 2 diabetes 1. Toth-Manikowski S & Atta MG. J Diabetes Res 2015;2015:697010;2. Stewart JH et al. Nephrology 2007;12:520; 3. Thomas MC et al. Nat Rev Nephrol 2016;12:73; 4. Reidy K et al. J Clin Invest 2014;124:2333; 5. United States Renal Data System. Am J Kidney Dis 2003;42:1; 6. Afkarian M et al. J Am Soc Nephrol 2013;24:302; 7. National Kidney Foundation. Diabetes. 2015. www.kidney.org/atoz/content/diabetes (Accessed Sep 2017) Diabetes leads to micro and macrovascular complications Approximately 50% of those with T2D will eventually suffer from CKD3,7 ~50%
  • 3. 0 15 30 45 60 75 N=6,034 N=11,253 N=4,685 N=2,437 All-cause mortality rate (per 1000 person-years) 3 Kidney disease is a stronger risk factor for mortality than a prior CV event CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction Tonelli M et al. Lancet 2012;380:807-814 Previous MI Diabetes + CKD CKD (eGFR <60) Diabetes 2x
  • 4. T2D, type 2 diabetes; GFR, glomerular filtration rate Percentages indicate excess mortality above the reference group (individuals with no diabetes or kidney disease) Afkarian M et al. J Am Soc Nephrol 2013;24:302 Patients with T2D and kidney disease have higher mortality rates than those without kidney disease 10 0 20 30 40 60 50 70 No kidney disease Albuminuria Impaired GFR Albuminuria & impaired GFR Reference group Standardised 10-year cumulative incidence of mortality (%) 4.1 17.8 23.9 47.0 Excess mortality Increased mortality
  • 5. T2D –CKD-CVD : The connecting link 5
  • 6. CKD, chronic kidney disease Moen MF et al. Clin J Am Soc Nephrol 2009;4:1121 Risk of hypoglycaemia is increased in CKD 8.4 4.1 1.6 1.0 1 0 2 4 3 5 8 7 6 9 +CKD/ +diabetes –CKD/ +diabetes +CKD/ –diabetes –CKD/ –diabetes Risk of severe hypoglycaemia (incidence rate ratio) With declining renal function, there is decreased clearanceof insulin.
  • 7. Challenges in optimising glycaemic control in CKD The management of glucose levels is particularly challenging in these patients, with the concomitant need to avoid hypoglycaemic events while managing renal comorbidities, often accompanied by CVD and/or other significant comorbidities2 Dose adjustment or cessation may be required for oral antidiabetic agents excreted by the kidney1 With declining renal function, there is decreased clearance of insulin1 Need to avoid hypoglycemia Reduced renal gluconeogenesis with declining renal mass1 CKD, chronic kidney disease; CVD cardiovascular disease. 1. KDOQI. Am J Kidney Dis 2012;60: 850–86. 2. Sherwin et al. J Clin Invest 1976;57: 722–31. 3. Defronzo et al. J Clin Invest 1978;62: 425–35.
  • 8.  Concern regarding the long term CV and renal safety of anti-hyperglcemic agents have been raised in several studies following publication of meta- analysis in 2007 that ROSIGLITAZONE increased the risk of MI and in 2009, RECORD trial showed that adding ROSIGLITAZONE increased the risk of heart failure  DDP4 Inhibitor – the net effect is a reduction in glucagon level and increased INSULIN secretion.  Most of the DPP4 inhibitors have neutral effects on CV events(proved by many CVOT trials).  LINAGLIPTIN is safe for CV and RENAL side effects.(CARMELINA TRIAL in subjects with high cardio-renal risks) ANTI HYPERGLYCEMIC AGENTS CHOICE: Concern on long term CV and renal safety - 8
  • 9. 9 CARMELINA® was specifically designed and statistically powered to evaluate both CV and Kidney Outcomes CARMELINA: Pre-specified adjudicated composite renal endpoints  Sustained ESRD  Sustained reduction in eGFR >40%  Renal Death 1. Scirica BM et al. N Engl J Med 2013;369:1317; 2. White WB et al. N Engl J Med 2013;369:1327; 3. Green JB et al. N Engl J Med 2015;373:232; 4. Rosenstock J et al. Cardiovasc Diabetol 2018;17:39 Renal safety and potential benefits of Linagliptin has been proven with CARMELINA. Perception : All DPP-4i are kidney safe, it is not exclusive to Linagliptin What could be the clinical impact of a prespecified renal endpoint safety evidence as recorded from the CARMELINA trial? EXPERT OPINION
  • 10. Linagliptin has proven Safety and Effectiveness Across the Spectrum of Chronic Kidney Disease Mild RI1 Moderate RI1 Severe RI2 ESRD and Hemodialysis3 New - Onset Diabetes After Transplant4 -0.7% -0.7% -0.7% -1% -0.6% 1. Cooper M, et al. ADA 2011, Poster 1068-P. 2. McGill JB, et al. Diabetes Care. 2013;36:237–244. 3. Kono T et al. 58th Ann Mtg of the Japanese Society for Dialysis Therapy (JSDT), Fukuoka, J Jpn Soc Dial Ther 2013. 46 (Suppl 1):670. 4. Sanyal, et al Indian J Endocr Metab 2013;17:S203-5. 5. Bae J et al. Endocrinol Metab (Seoul). 2016 Jan 6. PMID: 26754588 HbA1c Reductions with Linagliptin Across CKD Spectrum -1.4% Diabetes in Renal Transplant5 Preserved eGFR over 1-year2
  • 11. CV safety of DPP-4i in patients with kidney disease has been appropriately studied in CARMELINA 11 Schernthaner, Guntram et al.Diabetes Research and Clinical Practice, Volume 153, 30 - 4 The safety of linagliptin in patients with kidney disease, has been appropriately studied only in CARMELINA: 74% of trial population were having ‘prevalent kidney disease‘* *Defined as eGFR <60 ml/min/1.73 m2 or macroalbuminuria (UACR ≥300 mg/g
  • 12. CARMELINA demonstrated long-term kidney safety with Linagliptin CV, cardiovascular; CVOT, cardiovascular outcomes trial; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; VEGF, vascular endothelial growth factor †ESKD, renal death, ≥50% decrease in eGFR, albuminuria progression, use of retinal photocoagulation or intravitreal injections of an anti-VEGF therapy for diabetic retinopathy, or vitreous haemorrhage or diabetes-related-blindness 1. Scirica BM et al. N Engl J Med 2013;369:1317; 2. White WB et al. N Engl J Med 2013;369:1327; 3. Green JB et al. N Engl J Med 2015;373:232; 4. Boehringer Ingelheim. Data on file. 2018 12 HR (95% CI) HR (95% CI) p-value Prespecified adjudicated kidney composite outcome Other DPP-4i CVOTs 1-3 Not studied ESKD, renal death or ≥40% eGFR decrease 4 1.04 (0.89, 1.22) 0.6164 ESKD or renal death 0.87 (0.69, 1.10) 0.2371 Prespecified microvascular composite outcome † 0.86 (0.78, 0.95) 0.0032 Albuminuria progression 0.86 (0.78, 0.95) 0.0034 0.5 1.0 2.0 Favours linagliptin Favours placebo ?
  • 13. 13 UACR reduction ≥50% 14% Lower Risk of Progression of Albuminuria 14% RRR 15% Greater Likelihood of Significant Regression in UACR 15% Learnings from CARMELINA Trial: Risk Reduction for Albuminuria with Linagliptin Julio Rosenstock, Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial, JAMA, nov 2018
  • 14. Participants: Type 2 DM Plus CVD or Renal disease Interventions: 5mg Linagliptin vs Placebo Outcomes: 3P-MACE, Kidney outcome Conclusion: Individuals with T2D and NRP having a high disease burden, Linagliptin reduces their albuminuria burden and HbA1c, without affecting CV or kidney risk. 14
  • 15. Reno-protective effects of linagliptin 1,2  Inhibition of podocyte injury and apoptosis  Inhibition of myofibroblast transformation  Increased GLP-1 receptor expression 1. Mima A et al. Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes. Sci Rep. 2020; 10: 5775.79-7 2. Sharkovska Y. J Hypertens. 2014 Nov;32(11):2211-23 Possible Mechanisms for Kidney Protection in Pre-clinical Studies • Linagliptin can inhibit endothelial to mesenchymal transition (EndMT), thus ameliorates diabetic kidney fibrosis and progressive CKD • Such effects of Linagliptin were drug- specific, but not class effects
  • 16.  Linagliptin did not affect glomerular filtration rate (GFR), effective renal plasma flow (ERPF) or any intrarenal hemodynamic functions, compared to Glimepiride  Linagliptin was associated with modest natriuresis, possibly mediated by SDF-1α, with increase in fractional excretion of sodium (FENa) and potassium (FEK) The RENALIS Study: Effect of Linagliptin on Fasting Renal Hemodynamics 16 After 8 weeks of treatment in overweight T2D patients without renal impairment: Muskiet MHA, et al. Diabetes Care 2020;dc200902 [DOI: 10.2337/dc20-0902]
  • 17. With its unique mode of elimination, Linagliptin is the only available DPP-4 inhibitor that does not require dose adjustment for any stage of renal impairment Perception : Linagliptin is useful only in T2D with CKD Patients Any opinion regarding the same?
  • 18. Baseline Characteristics of DPP-4i CVOTs 18 Renal Risk Cardiovascular Risk Low CV & Kidney Risk High CV Risk High CV & Kidney Risk With CARMELINA & CAROLINA, linagliptin has been studied in Patients across Cardio-Renal Risk Continuum Median T2D duration 6.3 years Median T2D duration 14.75 years Jennifer B. Green, Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes, n engl j med 373;3 nejm.org july 16, 2015. Benjamin M. Scirica,, Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, n engl j med 369;14 nejm.org october 3, 2013. William B. White, Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes, n engl j med 369;14 nejm.org october 3, 2013. Julio Rosenstock, Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial, JAMA. doi:10.1001/jama.2018.18269 Published online November 9, 2018. Julio Rosenstock, Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes The CAROLINA Randomized Clinical Trial, JAMA. 2019;322(12):1155-1166. doi:10.1001/jama.2019.13772 Published online September 19, 2019.
  • 19. CAROLINA® and CARMELINA® provide evidence across a broad spectrum of T2D disease duration, CV and kidney risk CV, cardiovascular; T2D, type 2 diabetes 1. Rosenstock J et al. ADA 2019; 2. Rosenstock J et al. JAMA 2019;321:69 19 Atherosclerosis Chronic kidney disease Target-organ damage Risk 42% Median T2D duration 6.3 years Had established CV disease Displayed ≥2 defined CV risk factors Had T2D for ≤5 years Active- comparator Treatment naïve On insulin On metformin 37% 40% 9% 0% 83% 74% Mean T2D duration 14.75 years Prevalent kidney disease Had established CV disease Had established CV disease and prevalent kidney disease Placebo- controlled Treatment naïve On metformin On insulin 57% 33% <3% 55% 58% Early disease Advanced disease CAROLINA®1 CARMELINA®2 Asymptomatic Symptomatic
  • 20. CAROLINA® Linagliptin, n/N (%) Glimepiride, n/N (%) HR (95% CI) p-value 3P-MACE 356/3023 (11.8) 362/3010 (12.0) 0.98 (0.84, 1.14)* 0.7625 HHF or CV death 236/3023 (7.8) 234/3010 (7.8) 1.00 (0.84, 1.20) 0.9671 All-cause mortality 308/3023 (10.2) 336/3010 (11.2) 0.91 (0.78, 1.06) 0.2263 Together CARMELINA and CAROLINA Demonstrate Long-term Safety of Linagliptin in Patients Across Cardio-renal Risk Continuum CARMELINA® Linagliptin, n/N (%) Placebo, n/N (%) HR (95% CI) p-value 3P-MACE 434/3494 (12.4) 420/3485 (12.1) 1.02 (0.89, 1.17) 0.7398 HHF or CV death 406/3494 (11.6) 422/3485 (12.1) 0.94 (0.82, 1.08) 0.3881 All-cause mortality 367/3494 (10.5) 373/3485 (10.7) 0.98 (0.84, 1.13) 0.7402 *95.47 CI. 3P-MACE, 3-point MACE; 4P-MACE, 4-point MACE; CV, cardiovascular; HF, heart failure; HHF, hospitalisation for HF; MACE, major adverse CV events; MI, myocardial infarction Rosenstock J et al. JAMA 2019;321:69; Rosenstock J et al. ADA 2019
  • 21. Linagliptin has Proven CV and Renal Safety Across the Spectrum of CKD in T2DM *P value of subgroup-by-treatment interaction test. Adapted: Perkovic V et al. Diabetes Care. 2020 May 22;dc200279 CARMELINA Study: Patients of T2DM with CVD and/or CKD
  • 22. Linagliptin Placebo HR (95% CI) HR (95% CI) p-value for treatment by age interaction n with event / N analysed (%) 3P-MACE 434/3494 (12.4) 420/3485 (12.1) 1.02 (0.89, 1.17) 0.0937 <65 years 154/1467 (10.5) 140/1501 (9.3) 1.11 (0.89, 1.40) 65 to <75 years 197/1405 (14.0) 182/1395 (13.0) 1.09 (0.89, 1.33) ≥75 years 83/622 (13.3) 98/589 (16.6) 0.76 (0.57, 1.02) HHF 209/3494 (6.0) 226/3485 (6.5) 0.90 (0.74, 1.08) 0.9788 <65 years 67/1467 (4.6) 77/1501 (5.1) 0.87 (0.63, 1.21) 65 to <75 years 89/1405 (6.3) 99/1395 (7.1) 0.89 (0.67, 1.18) ≥75 years 53/622 (8.5) 50/589 (8.5) 0.92 (0.63, 1.35) Kidney outcome* 327/3494 (9.4) 306/3485 (8.8) 1.04 (0.89, 1.22) 0.9968 <65 years 180/1467 (12.3) 173/1501 (11.5) 1.05 (0.85, 1.29) 65 to <75 years 113/1405 (8.0) 105/1395 (7.5) 1.06 (0.81, 1.38) ≥75 years 34/622 (5.5) 28/589 (4.8) 1.06 (0.64, 1.75) Albuminuria progression 763/2162 (35.3) 819/2129 (38.5) 0.86 (0.78, 0.95) 0.4318 <65 years 289/816 (35.4) 308/829 (37.2) 0.93 (0.79, 1.09) 65 to <75 years 320/903 (35.4) 339/877 (38.7) 0.84 (0.72, 0.98) ≥75 years 154/443 (34.8) 172/423 (40.7) 0.78 (0.63, 0.97) CARMELINA: No increased risk of cardio-renal events in older patients 0.25 0.5 1 2 4 Favours linagliptin Favours placebo *Death due to kidney disease, progression to end-stage kidney disease, or sustained decrease in estimated glomerular filtration rate from baseline of ≥40% Cooper M et al. Diabetes Obes Metab 2020; Feb 9. doi: 10.1111/dom.13995 [Epub ahead of print]
  • 23. Summary: Linagliptin has Broadest Clinical Evidence in DPP-4i class 23 Uncertain Proven safety High CV risk Heart failure High kidney risk Proven safety Proven safety Safety Signal Proven safety Proven safety Uncertain Proven safety Uncertain Uncertain Safety signal Uncertain‡ Uncertain Uncertain Sitagliptin4, 5, 6 Teneligliptin3, 8 Linagliptin7 Saxagliptin2 Vildagliptin1 1. Novartis Europharm Ltd. Galvus® (vildagliptin) summary of product characteristics; 2. Scirica B et al. N Engl J Med 2013;369:1317; 3. Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):11-17; 4. Green J et al. N Engl J Med 2015;373:232; 5. Engel SE et al. Diabetes Obes Metab 2017;19:1587; 6. Merck Sharp & Dohme Ltd. Januvia® (sitagliptin) summary of product characteristics; 7. Trajenta PI 9 April 2020. Boehringer Ingelheim. 8. Singh AK. Efficacy and safety of teneligliptin. Indian J Endocr Metab 2017;21:11-7. + convenience of OD dosing without the need of dose adjustment
  • 24. Summary : Simplifying T2DM Care with Linagliptin 24 Proven Effectiveness and Safety Across Broad Range of Patients No need for dose-adjustment, in any stage of CKD Long Half-life (>100 hours), Ensuring Effective 24-hour Glycaemia Control 5mg one dose, once daily independent of: CV Risk Trajenta PI Boehringer Ingelheim Pvt. Ltd. 09 Apr 2020